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Introduction. Data on recurrence after operation for intrahepatic cholangiocarcinoma (ICC) are limited.
We sought to investigate rates and patterns of recurrence in patients after operative intervention for ICC.
Methods. We identified 301 patients who underwent operation for ICC between 1990 and 2011 from an
international, multi-institutional database. Clinicopathologic data, recurrence patterns, and recurrence-
free survival (RFS) were analyzed.
Results. During the median follow up duration of 31 months (range 1–208), 53.5% developed a
recurrence. Median RFS was 20.2 months and 5-year actuarial disease-free survival, 32.1%. The most
common site for initial recurrence after operation of ICC was intrahepatic (n = 98; 60.9%), followed by
simultaneous intra- and extrahepatic disease (n = 30; 18.6%); 33 (21.0%) patients developed extra-
hepatic recurrence only as the first site of recurrence. Macrovascular invasion (hazard ratio [HR], 2.08;
95% confidence interval [CI], 1.34–3.21; P<.001), nodal metastasis (HR, 1.55; 95%CI, 1.01–2.45;
P = .04), unknown nodal status (HR, 1.57; 95% CI, 1.10–2.25; P = .04), and tumor size$5 cm (HR,
1.84; 95% CI, 1.28–2.65; P < .001) were independently associated with increased risk of recurrence.
Patients were assigned a clinical score from 0 to 3 according to the presence of these risk factors. The 5-year
RFS for patients with scores of 0, 1, 2, and 3 was 61.8%, 36.2%, 19.5%, and 9.6%, respectively.
Conclusion. Recurrence after operative intervention for ICC was common. Disease recurred both at intra-
and extrahepatic sites with roughly the same frequency. Factors such as lymph node metastasis, tumor
size, and vascular invasion predict highest risk of recurrence. (Surgery 2013;153:811-8.)From the Department of Surgery,a Johns Hopkins University School of Medicine, Baltimore, MD; Department
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x.doi.org/10.1016/j.surg.2012.12.005INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) is a rela-
tively rare, malignant tumor located within the he-
patic parenchyma. Despite its rarity, ICC is the
second most common primary hepatic malignancy,
after hepatocellular carcinoma, accounting for 5–
30% of all primary liver cancer cases. In fact, the
incidence of ICC in the Western hemisphere is ris-
ing; however, the reasons for this are poorly under-
stood.1,2 Although many patients present with
advanced and/or metastatic disease, a subset ofSURGERY 811
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812 Hyder et alpatients have liver only disease that may be amena-
ble to operative resection. Operative resection is
the only potentially curative therapy for patients
with ICC.3 Data from our group, as well as others,
have noted a 5-year survival after operative resec-
tion for ICC that ranges from 25 to 35%.4,5
Virtually all studies to date on outcomes after
operative management of ICC have focused exclu-
sively onoverall survival.4,6-15 Specifically, previous in-
vestigators have reported on prognostic factors
associated with worse overall survival. Data from
our own international, multi-institutional ICC group
have noted that higher tumor number, vascular
invasion, and lymph node metastasis are associated
with adverse survival outcomes.4 In contrast, data
on recurrence, patterns of recurrence, and disease-
free survival remain ill-defined. As systemic and lo-
coregional therapies emerge for the treatment of
ICC, data on patterns of recurrence (eg, intra- vs
extrahepatic) may help to inform treatment strate-
gies.16-18 Unfortunately, the few studies that have re-
ported recurrence data have been small (ie, <100
patients) and single center.5,19-22 As such, previous
studies have been limited by sample size and an in-
ability to generalize findings to other centers.
The aim of the current study was to investigate
the incidence and patterns of recurrence after
operative intervention for ICC. Specifically, we
sought to examine which clinicopathologic factors
were associated with recurrence after operative
management of ICC.
METHODS
Between April 1990 and September 2011, 301
patients with nonmetastatic ICC treated primarily
with curative intent operative resection were iden-
tified from 12 major hepatobiliary centers in the
United States (The Johns Hopkins School of
Medicine, Baltimore, MD; Duke University Medical
Center, Durham, NC; University of Virginia, Char-
lottesville, VA; University of Pittsburgh Medical
Center, Pittsburgh, PA; Massachusetts General
Hospital, Boston, MA; Medical College of Wiscon-
sin, Milwaukee, WI) and Europe (University Hos-
pital Essen, Essen, Germany; Institute for Digestive
Diseases and Liver Transplantation Fundeni, Bu-
charest, Romania; Curry Cabral Hospital, Lisbon,
Portugal; Ospedale San Raffaele, Milan, Italy;
Cliniques Universitaires Saint-Luc, Brussels, Bel-
gium; Ho^pitaux Universitaires de Geneve, Geneva,
Switzerland). The study was approved by the insti-
tutional review boards of the respective institu-
tions. Only patients with histologically confirmed
ICC who underwent initial treatment for ICC at a
study center were included.Data collection. As previously described,4 pa-
tients were evaluated with a baseline history and
physical examination, serum laboratory tests, and
appropriate imaging studies (eg, computed tomog-
raphy or magnetic resonance imaging of the abdo-
men and pelvis and chest radiography or a chest
computed tomography) at the discretion of the
treating physician. Tumor characteristics were
noted on imaging. Patients were considered poten-
tial surgical candidates if all disease was felt to be
potentially resectable with curative intent with an-
ticipated R0 resection and there was no evidence
of extrahepatic disease. Data on treatment-related
variables, such as type of operation, receipt of lym-
phadenectomy, and adjuvant therapy, were also ob-
tained. Resection was classified as less than
hemihepatectomy, hemihepatectomy, extended
hepatectomy, or central hepatectomy. Margin and
nodal status were ascertained based on final path-
ologic review by a dedicated hepatobiliary patholo-
gist. The tumors were morphologically classified
using the Liver Cancer Study Group of Japan crite-
ria, and staged using the TNM classification.23,24
Patients with Nx disease were staged according to
the T category status only. After surgery, all patients
were regularly followed and prospectively moni-
tored for recurrence with computed tomography
or magnetic resonance imaging of the abdomen
and a chest radiograph every 3–4 months up to 2
years, and then every 6 months thereafter until
year 5, after which screening occurred annually.
Date of last follow-up, vital status, and
recurrence-related information were collected for
all patients. Recurrence was defined as a lesion that
was biopsy-proven recurrent cholangiocarcinoma
or a lesion that was deemed suspicious on cross-
sectional imaging in the setting of an elevatedCA19-
9 level. Information regarding the location, receipt
of curative intent treatment for the recurrence, as
well as the disease-free interval from the date of
initial operation to the development of recurrent
disease was recorded. Although the specific site of
all recurrences were collected, for the purposes of
analyses, recurrences were classified as intrahepatic
only, extrahepatic only, or intra- and extrahepatic.
Statistical analyses. Summary statistics were
obtained using established methods and presented
as percentages, mean, or median values. Time to
recurrence and survival were estimated using the
Kaplan---Meier method and differences were com-
pared using the log-rank test. Multivariate Cox
regression analysis was performed to explore asso-
ciations of factors with recurrence free survival.
Hazard ratios and 95% confidence intervals (CI)
were estimated. Factors were entered into the
Table I. Clinicopathologic features of 301 patients
Variable No. of patients (%)
Age (yrs)
<60 160 (53.5)
$60 140 (46.5)
Gender
Female 132 (43.9)
Male 169 (56.2)
Tumor no.
Solitary 225 (74.8)
Multiple 76 (25.3)
Vascular invasion
Absent 207 (68.8)
Present
Microscopic 39 (13.0)
Major 55 (18.3)
Node status
N1 50 (16.6)
N0 132 (43.9)
Nx 119 (39.5)
American Joint Committee on Cancer T category
T1 175 (58.1)
T2 66 (21.9)
T3 53 (17.6)
T4 7 (2.3)
Type of operative resection
Less than hemihepatectomy 86 (28.6)
Hemihepatectomy 115 (38.2)
Extended hepatectomy
($5 liver segments)
100 (33.2)
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multiple imputation was utilized to account for any
missing data on specific factors.25,26 All statistical
tests were 2-tailed. Statistical analyses were per-
formed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Patient characteristics and overall survival.
Table I lists the clinicopathologic features of the
301 patients in the study. There were 169 men
(56.2%) and 132 women (43.9%). The median pa-
tient age was 64 years (range, 26–88). Most patients
had a solitary tumor (n = 225; 74.8%), and the
median tumor size was 7.2 cm(range, 0.7–21). Ama-
jority of patients had T1 category tumors (n = 175;
58.1%); fewer had T2 (n = 66; 21.9) or T3/T4 tu-
mors (n = 60; 20.0%). At the time of the operation,
the extent of hepatic resection was less than a hem-
ihepatectomy in 86 (28.8%) patients, a hemihepa-
tectomy in 115 (38.1%) patients, and an extended
hepatectomy in 100 (33.1%) patients.
Most patients underwent R0 resection (n = 244;
81.1%); a smaller number had an R1 resection (n =
57; 18.9%). Lymphadenectomy was performed in
182 patients (60.5%); 50 patients (16.6%) had
lymph node metastases. Patients who underwent
lymphadenectomy were more likely to be younger
(eg, <60 years), as well as have more advanced T
category tumors (both P < .05). Vascular invasion
was present in 94 patients: 39 (13.0%) had micro-
scopic invasion, and another 55 patients (18.3%)
had macrovascular invasion; 28 (9.3%) patients
had microscopic evidence of perineural invasion.
In the postoperative setting, 109 (36.2%) patients
underwent adjuvant therapy; in the overwhelming
majority of patients (n = 105; 95.4%) this consisted
of adjuvant chemotherapy with or without adju-
vant radiotherapy; the other 4 patients underwent
adjuvant radiotherapy only.
Recurrence patterns and recurrence-free sur-
vival. During a median follow up of 31.0 months,
most patients (n = 161; 53.5%) developed a recur-
rence. The most frequent site of initial recurrence
after surgery of ICC was intrahepatic (n = 98;
60.9%), followed by simultaneous intra- and extra-
hepatic disease (n = 30; 18.6%); 33 (21.0%) pa-
tients developed extrahepatic only recurrence as
the first site of recurrence.
Median overall survival was 37.8 months (95%
CI, 29.3–45.7). Median recurrence-free survival
(RFS) was 20.2 months (95% CI, 16.4–28.0).
Overall 1-, 3-, and 5-year actuarial RFS was 64.2%,
39.0%, and 32.1%, respectively (Fig 1).
Statistical analysis revealed several factors that
influenced RFS. On univariate analysis, tumor size$5 cm, nodal status, vascular invasion, multiple
tumor nodules, and perineural invasion were all
significant predictors of earlier recurrence. Patients
with tumor size $5 cm had a median RFS of 17.0
months; in comparison patients with tumors<5 cm
had a median RFS of 41.2 months (P < .001; Fig 2,
A). Patients with no lymph node metastasis (N0)
had a median RFS of 35.1 months compared with
15.1 months for patients with lymph node metasta-
sis (N1) and 15.6 months for node unknown lymph
node status (Nx; P = .01; Fig 2,B).Multiple tumors at
time of operation were also associated with an ear-
lier recurrence. Whereas patients with solitary tu-
mors had a median RFS of 21.8 months, those
with multiple tumors had a median RFS of 18.8
months (P = .04). The presence of vascular invasion
and perineural invasion was strong predictors of
RFS (Fig 3). Among patients with no evidence of in-
vasion, median RFS was 28.0 versus 18.1 months for
patients with microscopic vascular invasion and 9.6
months for those with macrovascular invasion (P
< .001; Fig 3, A). Patients without perineural
invasion had a median RFS of 21.8 months com-
pared with 11.4 months for patients with perineural
Fig 1. Median RFS was 20.2 months (95% CI, 16.4–
28.0). Overall 1-, 3-, and 5-year actuarial RFS was
64.2%, 39.0%, and 32.1%, respectively. (Color version
of figure is available online.)
Fig 2. Tumor size and nodal status adversely affected the
RFS. A, Patients with tumor size $5 cm had a worse RFS
than those with smaller tumors. B, Patients with N0 dis-
ease also had a longer RFS than those with N1 and Nx
disease. (Color version of figure is available online.)
Surgery
June 2013
814 Hyder et alinvasion (P = .03; Fig 3, B). Univariate analysis re-
vealedno significant differences inRFS based on ad-
vanced age, extent of liver resection, receipt of
adjuvant therapy, postoperative margin status, pre-
operative jaundice, presence of hepatic cirrhosis,
presence of biliary invasion, or tumor histology
(all P > .05).
On multivariable analysis, tumor size $5 cm,
macrovascular invasion, and lymph node status
remained independent predictors of poor survival.
Patients with tumors$5 cmhad a greater likelihood
of recurrence than those with smaller tumors (HR,
1.84; 95% CI, 1.28–2.65; P < .001). Patients with
major vascular invasion had double the risk of recur-
rence compared with patients without vascular inva-
sion (HR, 2.08; 95% CI, 1.34–3.21, P < .001). In
contrast, patients with no lymph nodes metastasis
had a lower risk of recurrence compared with pa-
tient who had lymph node metastasis (HR, 1.55;
95% CI, 1.01–2.45; P = .04). Other factors such as
microvascular invasion, presence of multiple tu-
mors, and perineural invasion were not indepen-
dently associated with RFS (all P > .05; Table II).
Using the 3 independent variables---tumor size
$5 cm, major vascular invasion, and lymph node
status---a clinical score was devised in an attempt to
stratify patients with regard to prognosis. Patients
were assigned a score based on the sum of these
risk factors---patients lacking all 3 risk factors we
assigned a score of 0, patients with 1 risk factor
were assigned a score of 1, patients with 2 risk
factors assigned a score of 2, and patients with 3
risk factors were assigned a score of 3 (Fig 4). An
increasing risk score was associated with an incre-
mentally worse RFS. Specifically, patients with ascore of 0 had a median RFS of 75.2 versus 34.6
months for a score of 1, 11.1 months for a score
of 2, and 9.0 months for a score of 3 (P < .05 for
a score of 0 vs a score of 1 or 2 or 3). The 5-year
RFS for patients with scores 0, 1, 2, and 3 was
61.8%, 36.2%, 19.5%, and 9.6%, respectively.
To assess our clinical scoring system, patients
were also stratified by the American Joint Commit-
tee on Cancer TNM staging system, which is the
generally accepted classification system used after
resection. Under the TNM classification, patients
with stage 1 disease had the longest median RFS
(36.7 months) and better 5-year RFS rate (38.8%)
than patients with stage 2 or 3 disease (P < .05 for
comparison of stage 1 with either stages 2 or 3). Pa-
tients with stages 2 and 3 disease had median RFS
of 11.4 and 17.0 months, respectively. The 5-year
RFS for stage 2 was 18.2%, whereas patients with
stage 3 disease had a corresponding RFS rate of
Fig 3. Vascular and perineural invasion both predicted
poor survival.A, Patients with no vascular invasion,macro-
scopic, and microscopic invasion had a median RFS of
28.0, 9.6, and 18.1 months, respectively. B, Patients with
perineural invasion had a median survival of 11.4 months
compared with 21.8 months for patients without such in-
vasion. (Color version of figure is available online.)
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and the TNM stage is presented in Table III. The
clinical score accurately identified most patients
with early stage disease---97.4% of patients with a
score of 0 were TNM stage 1 or 2. However, an ad-
vanced clinical score did not always correlate with
an advanced TNM stage (ie, stage 3).
After recurrence at any site, median patient
survival duration was 11.8 months (95% CI, 8.0–
14.1). Among the 161 patients who developed a
recurrence, 33 (20.5%) patients underwent a re-
peat curative intent operation. Among those pa-
tients who were treated operatively for recurrence
with curative intent, the median survival was 25.8
months (95% CI, 18.1–45.2), whereas those trea-
ted with systemic chemotherapy or best supportive
care for the recurrence survived for a median
duration of 9.2 months (95% CI, 7.4–14.2; P = .01).DISCUSSION
ICC is the second most common primary liver
malignancy and the incidence of ICC is increasing
worldwide.21 Operative therapy has been shown to
be associated with survival in appropriately se-
lected patients.4,20 As with virtually all solid tumors,
the goal of operative intervention for ICC is com-
plete extirpation of the disease to ensure the great-
est chance of long-term cure. As such, most studies
on operative therapy for ICC have focused almost
exclusively on survival and those prognostic factors
associated with overall survival. However, data on
the incidence of recurrence and RFS are also im-
portant to patients and physicians. Although inter-
ested in the chance of cure and overall survival,
patients also want information on the risk of recur-
rence. For physicians, data on recurrence and the
specific patterns of recurrence can help to guide
postoperative surveillance, as well as inform future
therapeutic approaches. The current study is im-
portant because it defines the rate and pattern of
recurrence after curative intent surgery for ICC
in a large, multinational, multi-institutional cohort
of patients. We found that more than one half of
patients developed recurrence within 2 years.
When patients initially recurred, the pattern of fail-
ure was distributed relatively equally among intra-
and extrahepatic disease.
The disease-free survival reported in the present
study was notable for being 32.1% at 5 year with a
median RFS of only 20.2 months. Previous smaller
single-center studies had similarly high rates of
recurrence with poor disease-free survival.19,22 How-
ever, unlike previous studies, we also defined the
specific patterns of recurrence after curative intent
surgery for ICC. Specifically, of the 161 patients
who recurred, 60.9% patients recurred with liver
only disease, whereas 39.1%developed a recurrence
at an extrahepatic site with or without liver disease.
Of note, the risk of both intra- and extrahepatic re-
currence appeared to be highest over the first 24–36
months after surgery (Fig 1). Predictors of increased
risk of recurrence included factors typically associ-
ated with poor tumor biology such asmajor vascular
invasion and tumor size, among others. Interest-
ingly, we had previously reported that tumor size
was not associated with survival, whereas presence
of multiple tumors was associated with overall sur-
vival.8 In the current study, although the presence
of multiple tumors was associated with RFS on uni-
variate analyses, it was not on multivariate analyses.
In addition, we noted that tumor size was associated
with risk of recurrence, although it had not been as-
sociated with overall survival in our previously
Table II. Factors used in formulating the clinical score
Parameter
Recurrence-free survival
Hazard ratio
(95% CI) P value1 year (%) 3 year (%) 5 year (%) Median (mos)
Vascular invasion
None 68.8 44.8 35.2 28.0
Major vessel invaded 34.2 16.2 16.2 9.6 2.08 <.001
Tumor size (cm)
<5 77.4 55.8 47.6 41.2
$5 56.2 30.0 22.0 17.0 1.84 <.001
Lymph nodes status
N0 72.0 47.6 40.0 35.1
N1 59.8 20.4 20.4 15.1 1.55 .04
Nx 57.4 38.0 25.6 15.6 1.57 .04
Fig 4. RFS declined with an increasing clinical score.
The 5-year RFS for patients with scores 0, 1, 2, and 3
was 61.8%, 36.2%, 19.5%, and 9.6%, respectively. (Color
version of figure is available online.)
Table III. Relationship between clinical scoring
system and American Joint Committee on Cancer
TNM stage
Clinical
score
Total no.
patients
No. (%) of patients
Stage 1 Stage 2 Stage 3
0 38 26 (68.4) 11 (29.0) 1 (2.6)
1 141 89 (63.1) 20 (14.2) 32 (22.7)
2 53 37 (34.6) 17 (15.9) 53 (49.5)
3 15 2 (13.3) 5 (33.3) 8 (53.3)
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ancies is probably multifactorial. Others have simi-
larly noted that factors associated with recurrence
donot necessarily correlate with overall survival.27,28
Although certain factors may predict initial risk of
recurrence, the subsequent clinical course and nat-
ural history of the recurrence, as well as the progres-
sion of the disease leading to death, may be related
to other prognostic factors more indicative of un-
derlying disease biology such as vascular invasion
and nodal status---both of which we previously
reported were the main determinants of survival.
Future research needs to continue to refine
the prognostic factors associated with both
recurrence-free and overall survival.
Recently, there has been increasing interest in
the locoregional treatment of ICC not only oper-
atively, but also with intra-arterial therapy29 or
radiotherapy.30 To help better understand thepotential that local therapy might be able to pro-
vide for ICC, a better understanding of the natural
history and recurrence of ICC is needed. The pre-
sent study expands on our previous work and ex-
amines data on recurrence, RFS, and patterns of
recurrence. We noted that at 5 years disease-free
survival was only 32.1%. Collectively, our data sug-
gest that many patients treated with locoregional
therapy not only recur, but recur rapidly and at a
site outside their liver. As such, these data help to
highlight the need to incorporate systemic therapy
into future studies involving locoregional treat-
ments for ICC.
Slightly more than one third of these patients
underwent adjuvant therapy, most often consisting
of systemic chemotherapy. In the current series,
the use of adjuvant therapy was not associated with
a decreased risk of recurrence. The reason for this
is probably multifactorial. Given the respective
nature of the current trial, there was undoubtedly
some selection bias regarding who received adju-
vant therapy. In addition, given that only one third
of patients underwent adjuvant therapy, the
smaller number of patients in this subset may
have precluded our ability to detect an effect. In
general, the use of adjuvant therapy for cholangi-
ocarcinoma remains controversial and poorly
Surgery
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clinical prediction score herein proposed, may aid
not only in prognostication of patients with ICC
but also identify those patients at greatest risk of
recurrence. In turn, such a risk score may assist in
the selection of patients for receipt of adjuvant
chemotherapy, because the subset of patients who
should undergo such therapy remains unclear.
We demonstrated that disease-free survival mir-
rored overall survival, suggesting a high case fatal-
ity once recurrence occurs. Our finding that
median survival was about 12 months among
patients who recurred further supports this notion;
in addition, this median survival was comparable
with recently published prospective data on pa-
tients with advanced disease. Specifically, Valle
et al16 reported on 410 patients with locally ad-
vanced or metastatic cholangiocarcinoma, gall-
bladder cancer, or ampullary cancer to receive
either cisplatin followed by gemcitabine or gemci-
tabine alone. The authors reported that after a me-
dian follow-up of 8.2 months, the median overall
survival was 11.7 months among the 204 patients
in the cisplatin-gemcitabine group and 8.1 months
among the 206 patients in the gemcitabine group
(hazard ratio, 0.64; 95% CI, 0.52–0.80; P <
.001).16 As such, cisplatin plus gemcitabine has
generally been accepted as the appropriate option
for the treatment of patients with advanced biliary
cancer. Whether this regimen will have a defined
role in the adjuvant setting---and for what subset
of patients---remains to be determined.
The current study had limitations that should
be considered. Because our study is retrospective
in nature, there may have been selection/detec-
tion bias. Similar to previous reports from our
group, although all centers queried institution-
wide databases for information on recurrence, it is
conceivable that the extent of extrahepatic recur-
rences may be underrepresented owing to the
surgical nature of the databases utilized in the
current study.31 These limitations are inherent,
however, in nearly all retrospective analyses of
data on recurrence. The small number of patients
in some subsets (eg, <20% of cohort had an R1
margin) may have resulted in a type II error in as-
sessing the difference between some potential
prognostic factors. Finally, the absence of any cen-
ters from Asia/Eastern centers is another limita-
tion of the current study. ICC findings based
exclusively on a Western experience may not nec-
essarily be applicable to ICC in the East. As such,
future studies will not only need to validate the cur-
rent clinical risk score, but also need to include
data from Asian centers.In conclusion, although 5-year survival after
curative intent surgery for ICC was 32.1%, recur-
rence after resection was common. In fact, more
than half of patients recurred by 3 years and the 5-
year actuarial risk of both intra- and extrahepatic
recurrence was >60%. The site of recurrence was
relatively equally distributed with disease recurring
both in the liver and at extrahepatic sites. Factors
associated with recurrence included vascular inva-
sion, tumor size, and lymph node metastasis. Data
from the current study suggest that cure after
resection of ICC remains an elusive goal. Future
efforts needs to be aimed at better understanding
the carcinogenesis and pathogenesis of ICC to
identify more effective systemic therapeutic op-
tions for patients with this aggressive malignancy.
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